# EDGAR Filing Document

**Accession Number:** 0001488039
**File Stem:** 0001193125-26-213373
**Filing Date:** 2026-5
**Character Count:** 6695
**Document Hash:** d7b8182ac3c4975560a3d97ef24c6673
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-213373.hdr.sgml**: 20260508

**ACCESSION NUMBER**: 0001193125-26-213373

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260507

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260508

**DATE AS OF CHANGE**: 20260508

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ATOSSA THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001488039
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 264753208
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35610
- **FILM NUMBER:** 26956126

**BUSINESS ADDRESS:**
- **STREET 1:** 1448 NW MARKET STREET
- **STREET 2:** SUITE 500
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98107
- **BUSINESS PHONE:** 206.588.0256

**MAIL ADDRESS:**
- **STREET 1:** 1448 NW MARKET STREET
- **STREET 2:** SUITE 500
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98107

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ATOSSA GENETICS INC
- **DATE OF NAME CHANGE:** 20100325

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** May 7, 2026<br>

------

Atossa Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-35610 | 26-4753208 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 1448 NW Market Street, Suite 500 |  |  |
| Seattle**,** Washington |  | 98107 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code: (**206**)** 588-0256<br>

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.18 par value | ATOS | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On May 7, 2026, Atossa Therapeutics, Inc., a Delaware corporation (the "Company"), held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). As of the close of business on March 19, 2026, the record date for the Annual Meeting, there were 8,611,361 shares of common stock, par value $0.18 per share (the "Common Stock"), entitled to vote at the meeting.

At the Annual Meeting, each of the Company's director nominees was elected and each of the other proposals voted on was approved. The final voting results are set forth below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***(i)*** ***Election of Directors***

The stockholders elected the three Class II directors by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **Votes <br>For** | **Votes <br>Withheld** | **Broker**<br>**Non-Votes** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Stephen J. Galli, M.D. | 1,726,410 | 288,389 | 2,222,160 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Richard I. Steinhart | 1,730,171 | 284,628 | 2,222,160 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Tessa Cigler, M.D., M.P.H. | 1,750,694 | 264,105 | 2,222,160 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***(ii)*** ***Ratification of Independent Auditor***

The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Votes <br>For** | **Votes <br>Against** | **Abstentions**  | **Broker** <br>**Non-Votes** |
| 3,714,889 | 370,496 | 151,574 | 0 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***(iii)*** ***Approval of Amendment to the Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split of the Common Stock, if Deemed Necessary or Appropriate by the Board***

The stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio from 2:1 to 20:1, inclusive, if determined necessary or appropriate by the Board, by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Votes <br>For** | **Votes <br>Against** | **Abstentions**  | **Broker** <br>**Non-Votes** |
| 2,336,815 | 1,866,873 | 33,271 | 0 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***(iv)*** ***Advisory Vote on Executive Compensation***

The stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Votes <br>For** | **Votes <br>Against** | **Abstentions**  | **Broker** <br>**Non-Votes** |
| 1,530,390 | 444,616 | 39,793 | 2,222,160 |

---

------

\* \* \*

 **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | Atossa Therapeutics, Inc.  |
| Date: | May 8, 2026 | By:  | /s/ Mark J. Daniel |
|  |  |  | Mark J. Daniel<br>Chief Financial Officer |

---

------